FDA Extends Review of Application for Ocrevus (ocrelizumab)

South San Francisco, CA -- December 20, 2016 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news